Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2Zacks Investment Research • 06/24/25
Exelixis Surges On Positive Results For Next-Gen Colon Cancer DrugInvestors Business Daily • 06/23/25
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal CancerBusiness Wire • 06/22/25
Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine TumorsBusiness Wire • 06/20/25
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great ChoiceZacks Investment Research • 06/06/25
Exelixis (EXEL) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 05/23/25
Earnings Estimates Moving Higher for Exelixis (EXEL): Time to Buy?Zacks Investment Research • 05/23/25
EXEL Reports Superior Efficacy Data From Kidney Cancer Study CohortZacks Investment Research • 05/23/25
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025Business Wire • 05/22/25
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and JuneBusiness Wire • 05/22/25
Unlocking Exelixis (EXEL) International Revenues: Trends, Surprises, and ProspectsZacks Investment Research • 05/19/25